ArticleESMO open2019

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.

Matteo Lambertini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.